Related Experiment Video

Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Alternative therapy with ivabradine in patients with functional class III chronic heart failure]

S G Kanorskiĭ, V G Tregubov, V M Pokrovskiĭ

    Kardiologiia
    |September 28, 2011
    PubMed

    Insights

    Ivabradine effectively treats functional class III chronic heart failure (CHF) by improving exercise tolerance and cardiac function. This heart failure therapy offers an alternative when beta-blockers are not feasible.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic heart failure (CHF) with functional class (FC) III poses significant challenges.
    • Ischemic heart disease (IHD) and hypertensive disease (HD) are common comorbidities.

    Purpose of the Study:

    • To evaluate the efficacy of ivabradine in FC III CHF patients.
    • To assess ivabradine's impact on regulatory adaptive status (RAS).

    Main Methods:

    • 100 FC III CHF patients with IHD/HD received standard therapy.
    • Group 1 (n=56) received metoprolol succinate; Group 2 (n=44) received ivabradine.
    • Evaluations included exercise testing (VO2 max), echocardiography, BP monitoring, NT-proBNP, and cardio-respiratory synchronism.

    Main Results:

    • Ivabradine improved myocardial structure and function.
    • Exercise tolerance (VO2 max) and cardiovascular adaptation improved with ivabradine.
    • Positive changes in NT-proBNP levels were observed.

    Conclusions:

    • Ivabradine demonstrated efficacy in FC III CHF patients.
    • Ivabradine may serve as an alternative to beta-blockers when contraindicated or not tolerated.

    More Related Videos

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

    Published on: April 21, 2014

    Related Concept Videos

    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...